Deverra Therapeutics, Inc. is a clinical stage biotechnology company located in Seattle, Washington dedicated to the development of allogeneic, off-the-shelf  universal donor cellular immunotherapies to make on demand treatment of patients with cancer and infectious diseases possible. 

Our innovative and well-established platform can be used to generate a range of unmodified and modified (engineered) progenitor and immune cells to boost the patient’s blood and immune system to eliminate cancer and virally infected cells. Deverra’s team includes pioneers who were first to demonstrate clinical effectiveness using expanded stem cell therapies and  non-HLA matched, universal donor off-the-shelf cell therapies.

The company has exclusive license to the proprietary Notch-mediated stem cell expansion and directed differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and multiple  clinical trials.

OUR MISSION

 Dedicated to developing allogeneic universal donor cellular immunotherapies that are cost effective and accessible to all patients in need

LEADING THE WAY

Colleen Delaney

Scientific Founder, Chief Scientific Officer and EVP, Research & Development

Michael Yurkowsky

President and Co-Founder

Erika von Euw 

VP, Discovery and Translational Research

OUR PARTNERS

Research Partners

Cord Blood Bank Partners